Laboratory of Jeffrey A. Borgia, PhD

Jeffrey A. Borgia, PhD. is a graduate of the Biochemistry Graduate program at the University of Minnesota where he trained with Dr. Theodore R. Oegema, Jr. on proteoglycan biosynthesis. Dr. Borgia then completed postdoctoral studies with Dr. Gregg B. Fields where he explored the production of matrix metalloproteinases by melanoma cells when adhered to synthetic ‘mini-collagens’ as well as tumor cell aggressiveness. In 2002, Dr. Borgia joined the faculty at Rush in the Department of Biochemistry where he continued some of his work on proteoglycan biochemistry, but later elected to focus on cancer biology and the development of novel diagnostic tests with Dr. John S. Coon IV in the Department of Pathology. He is currently continuing these studies with appointments in both the Department of Cell & Molecular Medicine as well as the Department of Pathology.

Our work

  • Development of novel serum biomarkers to complement lung cancer screening programs that promote the early detection of lung cancer.
  • Investigating mechanisms underlying tumor metastasis in order to better prognosticate patient outcomes and identify novel biochemical targets for pharmaceutical development.
  • Studies into the mechanisms underlying rapid disease progression in lung cancer
  • Profiling of autoimmunity in relation to lung cancer progression and in the context of immune checkpoint inhibition strategies used in the patients with advanced-stage disease.
  • Pioneering new methods to enhance the delivery and long-term storage of blood-based (protein) biomarkers for diagnostic applications.

Back to top

Technology and methods

  • Agilent 6495 QQQ Mass Spectrometer with Agilent 1290 UHPLC system
  • Luminex FlexMAP 3D, Automated with an Agilent AssayMAP BRAVO and Biotek 405LS
  • Agilent 1260 HPLC system, multidimensional for offline protein fractionation
  • BioRad 1- and 2-dimensional electrophoresis workflow

Back to top


Here is a link to my PUBMED listed publications.

Back to top


  • NCI – R21CA22335 (Borgia – Principal Investigator) – ‘Targeted proteomics to aid in the management of patients with stage IA lung adenocarcinoma’.
  • NCI –‘the Cancer Driver Discovery Program (CDDP), Lung cancer’, Tissue Source Site (TSS).
  • Swim Across America – (Borgia – Principal Investigator) – ‘Autoantibodies associated with PD-1 immune checkpoint toxicity in lung cancer’.

Back to top

Our team

Research Laboratory Members
Darin Bagar (Graduate student)
Cristina Fhied, MS  (Scientist and Graduate student)
David Gerard, MS (Laboratory manager)
Kevin Little (Clinical research coordinator)
Rebecca Lopez (Manager research operations)
Hita Moudgalya, MD (Postdoctoral fellow)
Imad Tarhoni, MD, PhD (Postdoctoral fellow)
Conner Wakefield (Medical student)

Clinical Collaborators
Pulmonology – Mark A. Yoder, MD
Thoracic Surgery – Christopher W. Seder, MD; Michael J. Liptay, MD
Medical Oncology – Mary Jo Fidler, MD; Marta Batus, MD; Philip Bonomi, MD
Radiation Oncology – Guarav Marwaha, MD
Pathology – Paolo Gattuso, MD; Mark D. Pool, MD

Back to top


Jeffrey A. Borgia, PhD
Rush University Medical Center
Jelke Soutcenter, Suite 1412
1750 W. Harrison St.
Chicago, IL 60612
Office: (312) 942-7837

Back to top